Envista Holdings Corporation

NVST Healthcare Medical Instruments & Supplies

Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024. In the quarter to June 2026, revenue grew 7.10%, EPS grew 106.3%, free cash flow grew 37.6% and total debt was flat, each against the same quarter a year earlier.

22.90 0.60 −2.55%
Market cap
$3.8B
P/E
38.8×
Fwd P/E
24.4×
Dividend yield
—
F-score
7/9
Altman Z
1.59
Beneish M
−2.50
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

8 7 8 8
ROE
0.50% 1.56% 2.21% 3.06%
ROA
0.27% 0.85% 1.23% 1.69%
ROIC
3.47% 4.04% 4.36% 5.05%
Return on Tangible Assets
1.08% 3.20% 4.73% 6.57%
Average Days of Receivables
56.51 57.66 56.75 55.83
Free Cash Flow per Share
1.58 1.37 1.34 1.54
Free Cash Flow
263.10 230.90 220.30 249.00
Capital Expenditures
(37.00) (44.80) (51.80) (53.60)
Other line items
Cash ROIC
4.64% 4.00% 3.93% 4.42%
Accounts Receivable Turnover
6.57 6.86 6.77 6.65
Accounts Payable Turnover
7.15 6.73 7.60 7.06
Inventory Turnover
4.22 4.66 4.51 4.46
Average Days of Payables
48.53 56.73 48.96 54.30
Days of Inventory on Hand
90.47 85.30 86.49 83.04
Tax Rate
(0.90) (0.73) (0.66) (0.59)
Research and Development Expense of Revenue
4.14% 4.19% 4.23% 4.23%
Selling, General and Administrative Expense of Revenue
43.90% 42.53% 42.11% 41.43%
Share Based Compensation of Revenue
1.39% 1.38% 1.45% 1.42%
Interest Coverage
5.22 5.90 6.90 7.73
Operating CF/Net income
19.61 5.87 4.02 3.19
Depreciation/Fixed assets
0.53 0.52 0.52 0.53
Capex/Depreciation
(0.24) (0.29) (0.33) (0.35)
Revenue per Share
15.78 16.19 17.13 17.64
Operating CF per Share
1.81 1.64 1.66 1.87
Capex per Share
(0.22) (0.27) (0.32) (0.33)
Capex to Sales
0.01 0.02 0.02 0.02

Fold the line items

Columns are period end dates